Trials / Withdrawn
WithdrawnNCT04159610
Assessment of Safety, Tolerability and Efficacy of 1% GPB Cream Versus Qbrexza® (Glycopyrronium) Cloth 2.4% Under Maximum-Use Conditions in Subjects with Primary Axillary Hyperhidrosis
A Randomized, Open-Label, Multiple Dose, Two-Period Crossover Study Evaluating Maximum Use 1% GPB Cream Versus Qbrexza® (Glycopyrronium) Cloth 2.4% in Men and Women with Primary Axillary Hyperhidrosis
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Dr. August Wolff GmbH & Co. KG Arzneimittel · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to investigate the safety, tolerability and efficacy of 1% GPB Cream compared to Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use under maximum use conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | WO3970 | Application of cream to each axilla |
| DRUG | Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use | Qbrexza should be applied to the clean, dry, intact skin, of your underarm areas only |
Timeline
- Start date
- 2019-12-01
- Primary completion
- 2020-10-01
- Completion
- 2020-10-01
- First posted
- 2019-11-12
- Last updated
- 2024-12-24
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04159610. Inclusion in this directory is not an endorsement.